,id,ticker,title,category,content,date,provider,url,article_id
14256,235771,VCEL,Vericel revenues up 31  in Q3  shares up 2  premarket,news,Vericel  VCEL  Q3 results  Revenues   14 3M   31 2    Operating Loss    4M    37 5    Net Loss    5 4M    19 4    Loss Per Share    0 16    57 9    Quick Assets   15 5M   32 6   No guidance given Shares are up 2  premarket on light volume Now read ,2017-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/vericel-revenues-up-31-in-q3-shares-up-2-premarket-839436,839436
14257,235772,VCEL,Vericel beats by  0 08  beats on revenue,news,Vericel  NASDAQ VCEL   Q4 EPS of  0 01 beats by  0 08 Revenue of  23 35M   41 3  Y Y  beats by  4 59M Press ReleaseNow read ,2018-03-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/vericel-beats-by-008-beats-on-revenue-1324531,1324531
14258,235773,VCEL,Vericel Q4 revenues up 42   shares ahead 8  premarket,news,Vericel  VCEL  Q4 results  Revenues   23 4M   41 8    Operating Income   1 2M  Net Income   0 3M  EPS   0 01  Quick Assets   26 9M   17 0   2018 Guidance  Net Product Revenues   73M   78M Shares are up 8  premarket on light volume Now read ,2018-03-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/vericel-q4-revenues-up-42-shares-ahead-8-premarket-1324520,1324520
14259,235774,VCEL,Healthcare Gainers   Losers as of 11 00 am  3 5 2018 ,news,Gainers  CLSD  39   VCEL  28   GTXI  23   AVGR  17   INFI  14  Losers  DERM  63   AEZS  12   HTBX  10   NBY  6   REPH  6  Now read ,2018-03-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare-gainers--losers-as-of-1100-am-352018-1325149,1325149
14260,235775,VCEL,Premarket analyst action   healthcare,news,Dexcom  NASDAQ DXCM  initiated with a Sell rating and  57  24  downside risk  price target at Goldman Sachs  NYSE GS   Initiated with Neutral rating at Guggenheim  Shares down 5  premarket  NuVasive   NASDAQ NUVA  initiated with Neutral rating and  47  12  downside risk  price target at Goldman Nevro  NYSE NVRO  initiated with Neutral rating and  83  4  downside risk  price target at Goldman Hill Rom Holdings  NYSE HRC  initiated with Neutral rating and  85  2  downside risk  price target at Goldman  ABIOMED   NASDAQ ABMD  initiated with Buy rating and  332  19  upside  price target at Goldman Penumbra  NYSE PEN  initiated with Buy rating and  145  28  upside  price target at Goldman Insulet  NASDAQ PODD  initiated with Buy rating and  105  24  upside  price target at Guggenheim Adamas Pharmaceuticals  NASDAQ ADMS  initiated with Outperform rating and  31  26  upside  price target at Leerink Senseonics Holdings  NYSEMKT SENS  initiated with Buy rating and  6  97  upside  price target at Guggenheim Vericel  NASDAQ VCEL  initiated with Outperform rating and  15  55  upside  price target at Leerink The Cooper Companies  NYSE COO  resumed with Neutral rating and  231  5  upside  price target at Goldman  Globus Medical   NYSE GMED  upgraded to Buy with a  57  16  upside  price target at Needham  Henry Schein   NASDAQ HSIC  upgraded to Outperform at Leerink GlaxoSmithKline  NYSE GSK  upgraded to Outperform at Exane  BNP Paribas   PA BNPP  UroGen Pharma  NASDAQ URGN  upgraded to Outperform with a  73  22  upside  price target at Raymond James AnaptysBio  NASDAQ ANAB  downgraded to Sector Perform at RBC Capital Markets Endo International  NASDAQ ENDP  downgraded to Neutral with a  7  22  upside  price target at Mizuho PTC Therapeutics  NASDAQ PTCT  downgraded to Underweight with  26  flat  price target at  Barclays   LON BARC  citing lack of revenue upside  Shares down 6  premarket Now read ,2018-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1377421,1377421
14261,235776,VCEL,Healthcare   Top 5 Gainers   Losers as of 11 00 AM  04 04 2018 ,news,Gainers  TENX  72   RXII  28   CPRX  13   VCEL  12   LOXO  8  Losers  SLS  22   MYND  17   INNT  16   CHEK  13   CLLS  12  Now read ,2018-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-04042018-1377999,1377999
14262,235777,VCEL,Midday Gainers   Losers  4 4 2018 ,news,Gainers  TENX  75   RXII  25   INTX  19   VCEL  18   PTI  16   RTTR  15   TOPS  17   CPRX  15   FTD  13   OSN  13   Losers  CLDR  39   SLS  21   TITN  18   RMGN  18   MYND  15   INNT  15   CLLS  13   CHEK  12   MIND  11   DAC  10   Now read ,2018-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/midday-gainers--losers-442018-1378328,1378328
14265,235780,VCEL,5 Nasdaq Composite Stocks That Braved The Index s Bloodbath ,opinion,Wall Street was afflicted by extreme volatility in 2018  following a fabulous 2017  Market volatility which first appeared in February on investors  concerns about hyper inflation aggravated in March  as result of the trade conflict between the United States and China Although Wall Street had a relatively smooth run in the next six months  the situation worsened significantly in the last three months of the year fueled by a plethora of factors   yield curve inversion  the recent rate hike and the Fed s tighter monetary stance  conflicting news related to trade war between the United States and China and concerns of a global economic slowdown Nasdaq Composite Plunges in 2018The Nasdaq Composite   one of the three major stock indexes of U S  stock market   erased all its gains made in 2018  Currently  the tech heavy index is down 10 3  year to date and a bear market   The tech laden index has now plunged 23 6  from the all time record high close achieved on Aug  29  On Dec 24  Nasdaq Composite closed at 6 192 92  marking its lowest closing since Jul 10  2017 The Nasdaq Composite s stiff fall in 2018 can be attributed to three reasons  First  lingering trade conflicts with China significantly dented the technology sector  China is a major source of inputs which are needed by most of the large cap tech stocks for their final products  Moreover  China also provides the largest market for these high tech products Second  introduction of tariffs in the range of 10    25  on Chinese exports of several important intermediary products of the tech sector raised the cost of production for these companies  Third  the Fed has hiked interest rate four times this year which raised the benchmark lending rate by 1  in 2018  Consequently  the cost of funds jumped up much to the disadvantage of the tech sector Tech Sector Likely to ReboundThe technology sector is benefiting from continued strong digital transformation environment  The last few years have witnessed a series of breakthroughs in cloud computing  predictive analysis  artificial intelligence  AI   self driving vehicles  digital personal assistants  and Internet of Things  IoT   which set the stage for strong growth The United States is all set to witness massive deployment of 5G super fast wireless network in 2019  This will significantly raise the demand for high tech handheld gadgets and micro processors  Moreover  continued enterprise investment in big data and analytics along with the adoption of Software as a Service  SaaS  presents significant growth opportunity several tech companies Additionally  fundamentals of the U S  economy remain robust  The U S  GDP grew 3 3  on an average in the first nine months of 2018  better than Trump administration s 3  target growth rate  The fourth quarter is likely to maintain the momentum driven by strong labor market with record low unemployment and solid consumer and business confidence 5 Nasdaq Stocks Stand Tall in 2018Despite a plummeting Nasdaq Composite  a few companies have survived the turbulence because of their internal strengths and are poised to perform well in 2019  We take a look at five such stocks that have emerged winners amid this volatility  All these stocks carry a Zacks Rank  1  Strong Buy   You can see  The chart below shows price performance of our five picks year to date Vericel Corp    NASDAQ VCEL   is focused on developing patient specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions   It has delivered average positive earnings surprise in all last four quarters with an average of 54 9   The company has expected earnings growth of 42  for current year  The Zacks Consensus Estimate for the current year has improved by 31  over the last 60 days Attunity Ltd    NASDAQ ATTU   is a leading global provider of data integration and Big Data management software solutions for the Workplace Applications market   It has delivered average positive earnings surprise of 235 6  in three of the last four quarters  The company has expected earnings growth of 550  for current year  The Zacks Consensus Estimate for the current year has improved by 73 1  over the last 60 days Amedisys Inc    NASDAQ AMED   is a leading provider of healthcare services in the United States  It operates through three segments  Home Health  Hospice  and Personal Care   It has delivered average positive earnings surprise of 16 6  in three of the last four quarters  The company has expected earnings growth of 62  for current year  The Zacks Consensus Estimate for the current year has improved by 5  over the last 60 days ACM Research Inc    NASDAQ ACMR   develops  manufactures and sells single wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips   It has delivered a positive earnings surprise in all last four quarters with an average of 130 9   The company has expected earnings growth of 152 6  for current year  The Zacks Consensus Estimate for the current year has improved by 92  over the last 60 days Crocs Inc    NASDAQ CROX   designs  develops  manufactures  markets  and distributes casual lifestyle footwear and accessories for men  women  and children worldwide   It has delivered average positive earnings surprise of 126 3  in three of the last four quarters  The company has expected earnings growth of 235  for current year  The Zacks Consensus Estimate for the current year has improved by 80  over the last 60 days In addition to the stocks discussed above  would you like to know about our 10 top tickers to buy and hold for the entirety of 2019 These 10 are painstakingly handpicked from over 4 000 companies covered by the Zacks Rank  They are our primary picks poised to outperform in the year ahead ,2018-12-26,Zacks Investment Research,https://www.investing.com/analysis/5-nasdaq-composite-stocks-that-braved-the-indexs-bloodbath-200370922,200370922
14266,235781,VCEL,4 Stocks With Recent Price Strength To Maximize Your Gains,opinion, In the stock game  winning means reaching a higher price   However  striking the right chord each time needs a fair amount of luck No matter how disciplined and systematic investors are  equity market volatility will always manage to get the better of them  While a few lucky ones rake in the moolah  others fall victim to ad hoc strategies One could resort to commonly used techniques to find beaten down stocks that have the potential to recover faster than others  However  even such investment choices bear the risk of disappointment  Particularly  one could fall into the value trap if the hidden weaknesses in selected stock are not identified So  wouldn t it be a safer strategy to look for stocks that are winners currently and have the potential to gain further Sounds a good idea  Here is how to execute it One should primarily target stocks that have recently been on a bull run  Actually  stocks seeing price strength recently have a high chance of carrying the momentum forward If a stock is continuously witnessing an uptrend  there must be a solid reason or else it would have probably crashed  So  looking at stocks that are capable of beating the benchmark that they have set for themselves seems rational However  recent price strength alone cannot create the magic  Therefore  you need to set other relevant parameters to create a successful investment strategy Here s how you should create the screen to shortlist the current as well as the potential winners Screening Parameters Percentage Change in Price  4 Weeks  greater than zero  This criterion shows that the stock has moved higher in the last four weeks Percentage Change Price  12 Weeks  greater than 10  This indicates that the stock has seen momentum over the last three months  This lowers the risk of choosing stocks that may have drawn attention due to the overwhelming performance of the overall market in a very short period Zacks Rank 1 or 2  No matter whether market conditions are good or bad  stocks with a Zacks Rank  1  Strong Buy  or 2  Buy  have a proven history of outperformance  You can see  Average Broker Rating 1 or 2  This indicates that brokers are also highly hopeful about the stock s future performance Current Price greater than 5  The stocks must all be trading at a minimum of  5 Current Price  52 Week High Low Range more than 85   This criterion filters stocks that are trading near their respective 52 week highs  It indicates that these are strong enough in terms of price Just these few criteria narrowed down the universe from over 7 700 stocks to just four Here are those four stocks Alteryx Inc    NYSE AYX   provides self service data analytics software platform that enhances productivity of business analysts  The company s stock price has advanced 1 5  in the last four weeks  It has expected earnings growth of 72 7  for current year  The Zacks Consensus Estimate for the current year has improved by 88  in the last 60 days  Alteryx recorded a positive earnings surprise of 132 6  in the trailing four quarters Vericel Corp    NASDAQ VCEL   researches  develops  manufactures  markets and sells patient specific expanded cellular therapies to repair and regenerate damaged tissues and organs  The company s stock price has advanced 0 7  in the last four weeks  It has expected earnings growth of 42  for current year  The Zacks Consensus Estimate for the current year has improved by 31  in the last 60 days  Verical delivered a positive earnings surprise of 54 9  in the trailing four quarters Mitek Systems Inc    NASDAQ MITK   develops  markets and sells mobile image capture and identity verification software solutions in the United States and internationally  The company s stock price has advanced 19 1  in the last four weeks  It has expected earnings growth of 37 9  for current year  The Zacks Consensus Estimate for the current year has improved by 2 5  in the last 60 days  Mitek Systems recorded a positive earnings surprise of 51 9  in the trailing four quarters Materialise NV   NASDAQ MTLS   provides additive manufacturing software and 3D printing services in Europe  the Americas  Africa  and the Asia Pacific  The company s stock price has advanced 40 6  in the last four weeks  It has expected earnings growth of 350  for current year  The Zacks Consensus Estimate for the current year has improved by 10  in the last 60 days  Materialise delivered a positive earnings surprise of 87 5  in the trailing four quarters The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-01-01,Zacks Investment Research,https://www.investing.com/analysis/4-stocks-with-recent-price-strength-to-maximize-your-gains-200372246,200372246
14267,235782,VCEL,Zacks com Featured Highlights Include  Alteryx  Vericel  Mitek And Materialise,opinion,For Immediate ReleaseChicago  IL   January 3  2019   Stocks in this week s article are Alteryx Inc    NYSE AYX    Vericel Corp    NASDAQ VCEL    Mitek Systems Inc    NASDAQ MITK   and Materialise NV   NASDAQ MTLS   4 Stocks with Recent Price Strength to Maximize Your Gains In the stock game  winning means reaching a higher price   However  striking the right chord each time needs a fair amount of luck No matter how disciplined and systematic investors are  equity market volatility will always manage to get the better of them  While a few lucky ones rake in the moolah  others fall victim to ad hoc strategies One could resort to commonly used techniques to find beaten down stocks that have the potential to recover faster than others  However  even such investment choices bear the risk of disappointment  Particularly  one could fall into the value trap if the hidden weaknesses in selected stock are not identified So  wouldn t it be a safer strategy to look for stocks that are winners currently and have the potential to gain further Sounds a good idea  Here is how to execute it One should primarily target stocks that have recently been on a bull run  Actually  stocks seeing price strength recently have a high chance of carrying the momentum forward If a stock is continuously witnessing an uptrend  there must be a solid reason or else it would have probably crashed  So  looking at stocks that are capable of beating the benchmark that they have set for themselves seems rational However  recent price strength alone cannot create the magic  Therefore  you need to set other relevant parameters to create a successful investment strategy Here s how you should create the screen to shortlist the current as well as the potential winners For the rest of this Screen of the Week article please visit Zacks com at  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-01-02,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-alteryx-vericel-mitek-and-materialise-200372548,200372548
14268,235783,VCEL,6 Stocks To Watch  AMSC  APYX  CIEN  ETSY  VCEL  VCRA,opinion,"American Superconductor Corporation  NASDAQ AMSC 
AMSC  a swing trade of ours was up a little fraction  and on Tuesday  it popped out of what looks like a little wedge  gained 52 cents  or 5   to 11 75  on 255 550 shares traded  I think it s going to make a run at the old high at 12 1 2  and then maybe get up to 14 1 2 15  my secondary target 
Apyx Medical Inc  NASDAQ APYX 
APYX had an inside  positive day on Tuesday  popping 25 cents  or 3 34   to 7 74  on nearly 300 000 shares traded  Not a lot of volume  but the technicals and OBV look good  OBV ran up near its high  I think that if it can get through the 8 8 1 2 zone  you are going to see 9 3 4  10  or better  going forward 
Ciena Corp  NYSE CIEN 
CIEN a swing trade  is looking really good  closing up 1 06  or 3   to 36 65  on 3 9 million shares with a high of 36 69  I think it has more to go  I m looking at something in the 48 to 55 zone on an intermediate basis 
Etsy Inc  NASDAQ ETSY 
ETSY had several good days in a row after the V bottom  and the right handed extended V held  It popped  and then ran  jumping 2 31  or 4 48   to 53 88  on 2 8 million shares  It may get a run up to 58 1 2  If it gets through that  I think it will be wildfire  Targets are in the mid 60s  eventually as high as 80 85 
Vericel Corp Ord  NASDAQ VCEL 
VCEL popped 60 cents  or 3 36   to 18 46  on nearly a million shares  up to key resistance near the high that tagged 18 87 on December 4  a little more than a month ago  and is right back up to 18 46  Near term target is 20 1 2  and then 22 
Vocera Communications  Inc   VCRA 
VCRA had a really nice reaction  and after testing the 50 and trendline  it popped  pulled back to retest  and then had a breakout  bouncing 1 43  or 3 57   to 41 52  on 452 867 shares traded  Resistance is at 42 40  which may be reached as early as Wednesday  and then a rush up towards 43  40 44 1 2  45 
Stocks On The Long Side
American Superconductor Corporation  AMSC   Apyx Medical Corporation  APYX   Axsome Therapeutics  Inc   AXSM   BRF S A   BRFS   CareDx  Inc  CDNA   Canopy Growth Corporation  CGC   Ciena Corporation  CIEN   Clovis Oncology Inc  NASDAQ CLVS   Crocs  Inc   CROX   eHealth  Inc   EHTH   Epizyme  Inc   EPZM   Etsy  Inc   ETSY   Exelixis  Inc   EXEL  Glu Mobile Inc   GLUU   Direxion Daily S P Biotech Bull 3X ETF  LABU   The Meet Group  Inc   MEET   Marin Software Inc  NASDAQ MRIN   Mirati Therapeutics  Inc   MRTX   NF Energy Saving Corporation  NFEC   Nektar Therapeutics  NASDAQ NKTR   Okta  Inc   OKTA   Tactile Systems Technology  Inc   TCMD   Tilray  Inc   TLRY   Tandem Diabetes Care  Inc   TNDM   VelocityShares 3x Lng Crude Oil ETN New  UWT   Vericel Corporation  VCEL   Vocera Communications  Inc   VCRA   VirnetX Holding Corp  VHC   vTv Therapeutics Inc  NASDAQ VTVT   Energous Co  NASDAQ WATT   and Xenon Pharmaceuticals Inc   XENE  
Watch video here ",2019-01-08,Harry Boxer,https://www.investing.com/analysis/amsc-apyx-cien-etsy-vcel-vcra-200373869,200373869
14269,235784,VCEL,Swing Trade Setups  Biotech Stocks Dominating,opinion,"In this article  I will discuss swing trade setups among the strongest stocks currently in the market  I look at the strongest 1 2  stocks  This means stocks having a relative strength rating of 99 or 98  I am interested in two major setups  a breakout  which I can buy intraday or an anticipation setup  which I can potentially buy the next day if it clears new 3 day high 
Here are a few anticipation setups for next week  GKOS  RARX  INSP  VCEL  and FN  As you can see  biotech stocks are dominating ",2019-02-03,Ivaylo Ivanhoff,https://www.investing.com/analysis/top-one-percent-stocks--feb-3rd-200382954,200382954
14270,235785,VCEL,What s In Store For Vericel  VCEL  This Earnings Season ,opinion,"Vericel Corporation   NASDAQ VCEL   is scheduled to report its fourth quarter 2018 and full year earnings results on Feb 26  2019 before market open 
The company s track record has been impressive so far  having surpassed estimates in three of the trailing four reported quarters while matching the same on one occasion  the average positive surprise being 54 88   In the last reported quarter  Vericel came up with a beat of 81 82  
Shares of Vericel have skyrocketed 162 9  in the past year against the  decrease of 17 7  

 
Let s see how things are shaping up for this quarter to be reported 
Factors to Consider
Vericel s top line consists of sales from its two marketed products  namely MACI and Epicel  Sales of both have increased year over year and sequentially in the third quarter of 2018  We expect this positive trend to continue in the fourth quarter as well  The company plans to raise MACI sales force by 20   adding a sixth sales region in 2019 
MACI  autologous cultured chondrocytes on porcine collagen membrane  was approved by the FDA in December 2016  It is an autologous cellularized scaffold product indicated for the repair of symptomatic  single or multiple full thickness cartilage defects of the knee with or without bone involvement in adults 
Vericel is focused on its goal of training approximately 900 surgeons by the end of the fourth quarter 2018  up from 500 trained practitioners at the end of 2017  The company also plans to expand MACI manufacturing capacity to meet growth in demand for the medicine  We expect management to provide an update on the same on fourth quarter conference call 
Epicel  cultured epidermal autografts  is a permanent skin replacement Humanitarian Use Device  HUD  used for treating patients with deep dermal or full thickness burns comprising greater than or equal to 30  of total body surface area  TBSA  
Last month  Vericel announced encouraging outcomes data for 954 burn patients treated with Epicel  The results showed that patients treated with Epicel experienced a higher survival rate compared with the data posted for patients at the National Burn Repository with comparable burns  The findings were published in the Journal of Burn Care and Research 
However  during third quarter investor call  Vericel stated that it does not expect significant growth for Epicel sales in the fourth quarter as compared to the previous reported quarters  It also said that revenues in the impending quarterly release will be entirely driven by MACI  We expect management to publish further news on the same on the upcoming earnings call 
Earnings Whispers
Our proven model does not conclusively show that Vericel is likely to beat estimates this quarter to be reported  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below 
Earnings ESP  Vericel has an Earnings ESP of  11 11   representing the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate wherein the former stands at 4 cents while the latter is pegged at 5 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Vericel carries a Zacks Rank  2  which increases the predictive power of ESP  However  the company s negative ESP leaves surprise prediction inconclusive as only a positive ESP in the combination can significantly raise the odds of a likely earnings surprise 
We caution against Sell rated stocks   4 and 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Vericel Corporation Price and EPS Surprise
   Stocks That Warrant a Look
Here are a few health care stocks that you may want to consider as our model shows that these have the right mix of elements to beat on earnings this reporting cycle 
Aduro Biotech  Inc    NASDAQ ADRO   has a Zacks Rank of 2 and an Earnings ESP of  15 23   You can see  
BioDelivery Sciences International  Inc    NASDAQ BDSI   is scheduled to release fourth quarter results on Mar 14  The company has an Earnings ESP of  38 46  and a Zacks Rank of 1 
Cara Therapeutics  Inc    NASDAQ CARA   is a Zacks  2 Ranked player and has an Earnings ESP of  11 36  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2019-02-22,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-vericel-vcel-this-earnings-season-200391740,200391740
14271,235786,VCEL,Vericel  VCEL  Tops On Q4 Earnings   Sales  Stock Up,opinion,Massachusetts based Vericel Corporation   NASDAQ VCEL   is a commercial stage biopharmaceutical company  The company generates revenue from its two marketed products  namely MACI and Epicel  Both the products have been performing well since their launch MACI is indicated for the repair of knee cartilage defects in adults using a patient s own cells  while Epicel is a permanent skin replacement used for treating patients with deep dermal or full thickness burns Vericel s performance has been pretty impressive so far  having surpassed estimates in three of the trailing four reported quarters while matching the same on one occasion  the average positive surprise being 54 88   Loss estimates have widened slightly over the past 60 days Currently  Vericel has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat Vericel surpassed earnings expectations  The company reported EPS of 11 cents while our consensus called for EPS of 5 cents  Earnings rose significantly year over year Revenues Beat  Revenues in the reported quarter also came above expectations  Vericel posted revenues of  31 3 million also above our consensus estimate of  29 2 million Key Stats MACI generated revenues of  25 1 million in the reported quarter  while Epicel registered sales  6 2 million Sales of both the products have increased year over year and sequentially in the fourth quarter of 2018 2019 Outlook Vericel issued a decent revenue guidance for 2019 The company expects total net product revenues to be in the range of  108 to  112 million in 2019 Stock Price Impact Shares were up almost 7 5  in pre market trading Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-02-25,Zacks Investment Research,https://www.investing.com/analysis/vericel-vcel-tops-on-q4-earnings--sales-stock-up-200392545,200392545
14272,235787,VCEL,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 68 ,news,"Investing com   U S  stocks were higher after the close on Tuesday  as gains in the Basic Materials  Industrials and Utilities sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average gained 0 68   while the S P 500 index gained 0 63   and the NASDAQ Composite index gained 0 64  
The best performers of the session on the Dow Jones Industrial Average were International Business Machines  NYSE IBM   which rose 2 55  or 3 06 points to trade at 123 12 at the close  Meanwhile   Caterpillar  Inc  NYSE CAT  added 2 31  or 2 92 points to end at 129 33 and The Travelers Companies Inc  NYSE TRV  was up 1 64  or 2 07 points to 128 60 in late trade 
The worst performers of the session were  Nike  Inc  NYSE NKE   which fell 1 24  or 0 96 points to trade at 76 57 at the close   Pfizer  Inc  NYSE PFE  declined 1 17  or 0 51 points to end at 43 01 and Intel Corporation  NASDAQ INTC  was down 0 88  or 0 42 points to 47 25 
The top performers on the S P 500 were  Mylan Inc   NASDAQ MYL  which rose 16 13  to 36 43  Symantec Corporation  NASDAQ SYMC  which was up 12 59  to settle at 22 54 and Mosaic Co  NYSE MOS  which gained 10 61  to close at 35 64 
The worst performers were Ralph Lauren Corp Class A  NYSE RL  which was down 6 59  to 127 79 in late trade  AmerisourceBergen  NYSE ABC  which lost 5 15  to settle at 84 00 and Marriott International Inc  NASDAQ MAR  which was down 5 08  to 114 55 at the close 
The top performers on the NASDAQ Composite were Boxlight Corp Class A  NASDAQ BOXL  which rose 92 71  to 3 70  Vericel Corp Ord  NASDAQ VCEL  which was up 44 28  to settle at 16 650 and Naked Brand Group Ltd  NASDAQ NAKD  which gained 43 36  to close at 2 050 
The worst performers were OncoSec Medical Inc  NASDAQ ONCS  which was down 49 82  to 0 873 in late trade  GreenSky LLC  NASDAQ GSKY  which lost 36 70  to settle at 9 28 and  iPass Inc   NASDAQ IPAS  which was down 34 64  to 1 1700 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 1906 to 1152 and 86 ended unchanged  on the Nasdaq Stock Exchange  1629 rose and 1011 declined  while 82 ended unchanged 
Shares in Mosaic Co  NYSE MOS  rose to 3 years highs  up 10 61  or 3 42 to 35 64  Shares in OncoSec Medical Inc  NASDAQ ONCS  fell to 5 year lows  falling 49 82  or 0 867 to 0 873  Shares in Vericel Corp Ord  NASDAQ VCEL  rose to 5 year highs  gaining 44 28  or 5 110 to 16 650  Shares in GreenSky LLC  NASDAQ GSKY  fell to all time lows  falling 36 70  or 5 38 to 9 28  Shares in iPass Inc  NASDAQ IPAS  fell to 52 week lows  losing 34 64  or 0 6200 to 1 1700  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 0 15  to 19 91 
Gold Futures for December delivery was down 0 13  or 1 60 to  1228 20 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 1 43  or 0 90 to hit  62 20 a barrel  while the January Brent oil contract fell 1 46  or 1 07 to trade at  72 10 a barrel 
EUR USD was up 0 09  to 1 1418  while USD JPY rose 0 23  to 113 45 
The US Dollar Index Futures was up 0 00  at 96 09 ",2018-11-06,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-higher-at-close-of-trade-dow-jones-industrial-average-up-068-1676708,1676708
14280,235795,VCEL,Vericel Sees Hammer Chart Pattern  Time To Buy ,opinion,Vericel Corporation   NASDAQ VCEL   has been struggling lately  but the selling pressure may be coming to an end soon  That is because VCEL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom What is a Hammer Chart Pattern  A hammer chart pattern is a popular technical indicator that is used in candlestick charting  The hammer appears when a stock tumbles during the day  but then finds strength at some point in the session to close near or above its opening price  This forms a candlestick that resembles a hammer  and it can suggest that the market has found a low point in the stock  and that better days are ahead Other FactorsPlus  earnings estimates have been rising for this company  even despite the sluggish trading lately  In just the past 60 days alone 4 estimates have gone higher  compared to none lower  while the consensus estimate has also moved in the right direction Estimates have actually risen so much that the stock now has a Zacks Rank  2  Buy  suggesting this relatively unloved stock could be due for a breakout soon  This will be especially true if VCEL stock can build momentum from here and find a way to continue higher of off this encouraging trading development  You can see Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ,2019-12-19,Zacks Investment Research,https://www.investing.com/analysis/vericel-sees-hammer-chart-pattern-time-to-buy-200493700,200493700
107045,328560,VCEL,4 Stocks To Watch  BHC  CGC  COLL  CRC,opinion,"Bausch Health Companies Inc   NYSE BHC  swing trade broke out above its June high on Wednesday  gaining 1 06  or 4   to 28 32  on 9 7 million shares  That s decent volume for this stock  It looks like it s headed to 32  and then high 30 s 
Canopy Growth Corporation  NYSE CGC  continues to consolidate  popping 3 54  or 8   to 49 28  on 8 million shares one Wednesday  It pulled back for 5 days  slightly took out a level of support  but held the trendline and two pullbacks at the trendline  If it holds that level without and further damage  it could always stop at 44 90  However  the targets going forward are 53 and 54 
Collegium Pharmaceutical  Inc   NASDAQ COLL  may have broken back out on again  It has been in a down channel for four months  On Wednesday  it spiked up 1 73  or 11   to 17 07  on 887 887 shares traded  That s the biggest volume on an up day in three months  It closed above the 50  but it didn t close above the prior high  Watch this one on Thursday  Targets are 17 1 2  and then 19 20
California Resources Corporation  NYSE CRC  broke out above its July high on Wednesday  jumping 1 35  or 3   to 49 97  on 175 million shares  and made a nominal new high on the rising channel as well  This one was pretty powerful  Look for it to run to 53  and then 60 and 62  if not more 
Stocks on the long side included Aurora Cannabis Inc   OTC ACBFF   Amarin Corporation plc  NASDAQ AMRN   Amyris  Inc   NASDAQ AMRS   Bausch Health Companies Inc   NYSE BHC   Canopy Growth Corporation  NYSE CGC   Collegium Pharmaceutical  Inc   NASDAQ COLL   California Resources Corporation  NYSE CRC   Dermira  Inc   NASDAQ DERM   Denbury Resources Inc   NYSE DNR   Intelsat S A   NYSE I   Idera Pharmaceuticals  Inc   NASDAQ IDRA   Kandi Technologies Group  Inc   NASDAQ KNDI   New Age Beverages Corporation  NASDAQ NBEV   Tilray  Inc   NASDAQ TLRY   Trevena  Inc   NASDAQ TRVN   VelocityShares 3x Long Natural Gas ETN  NYSE UGAZ   Vericel Corporation  NASDAQ VCEL   21Vianet Group  Inc   NASDAQ VNET   and ViewRay  Inc   NASDAQ VRAY  
Watch video here ",2018-10-04,Harry Boxer,https://www.investing.com/analysis/bhc-cgc-coll-crc-200346873,200346873
107047,328562,VCEL,3 Hot  Gap Up  Stocks To Buy Now  Plus 1 To Avoid ,opinion,"Current stock market conditions are not yet ideal for leaning on the  buy button   but here are three recent  high volume gap ups ready for pullback entry 
Stocks that have  gapped up on big volume are often the best stocks to buy 
This is especially true when a stock gaps to a new  all time high following a valid basing pattern 
Still  not every gap up is worth monitoring 
The gap ups we pay attention to are either breaking out from a base OR gapping above their 50 day moving averages within a base  press here for a quick review of basing patterns  
When a stock has already rallied 20  over a five week period and THEN gaps 15  higher  that is not  the type of gap we are looking for 
Continue reading to find out the best types of gap ups to buy  as well as our three top stock picks now  and one to avoid  
Under Armour Inc A  NYSE UAA    Gap Above Resistance
Under Armour  UAA  is a stock that recently landed on the  Wagner Daily watchlist due a high volume gap up 
On the daily chart below  notice that volume spiked to 10 times its average daily volume on the day it gapped above major moving average resistance 
The massive volume spike indicates institutional accumulation by fund managers  which is key for driving the stock higher in a legitimate breakout 

As long as UAA holds above its 10 day exponential moving average  teal line   we will continue to monitor the price action for potential buy entry 
A breakdown below the 10 day EMA would suggest the stock is headed lower in the short term  or needs another week or two of sideways chop  before heading higher 
FireEye Inc  NASDAQ FEYE    Ready To Gap   Go
Fireeye  FEYE  is another big volume gapper on our stock pick newsletter watchlist 
The recent gap up was accompanied by volume swelling to approximately 400  its average daily volume 
Like Under Armour  FEYE also gapped back above key resistance of its 10  50  and 200 day moving averages 
Tuesday s failed test of the prior high may lead to a buyable pullback to the 10 day EMA 

Vericel Corp Ord  NASDAQ VCEL    Massive Volume  Gap   Go   
Yesterday  Vericel  VCEL  investors were treated to a massive rally of nearly 50  that was driven by a huge opening gap on  800  average volume 
Unlike other stocks that have recently gapped up  VCEL also closed at its intraday high 
Massive volume gap ups from well defined bases often signal the beginning of powerful new uptrends 

The extremely bullish gap up means that VCEL will also be added to our watchlist for potential buy entry on a pullback 
Shoe Carnival  NYSE CCL   SCVL    Gaps Sometimes Fail 
As we mentioned earlier  not all gap ups are buyable on a pullback 
An example of a gap up failing to hold is Shoe Carnival  SCVL   back in September 
Here s why 

When a stock gaps on huge volume and then pulls back to the 10 day EMA  it usually presents a low risk buying opportunity to catch the next wave up 
However  when the price fails to hold the intraday low of the gap day AND its 10 day EMA support  on a closing basis   it is no longer in play for us 
Conclusion
If you patiently wait for the pullback of a gapped stock and have a proper entry  you must always be prepared to close the trade for a loss if the stock doesn t act right 
When the overall stock market is in questionable health  gap up stocks often provide the best opportunity for profitable stock trades 
However  be sure to follow the rules by waiting for a low risk entry point on the pullback  and be ready to bail out quickly if it does not follow through to the upside 
Original post",2018-11-08,Deron Wagner,https://www.investing.com/analysis/3-hot-gap-up-stocks-to-buy-now-plus-1-to-avoid-200356693,200356693
107049,328564,VCEL,4 Stocks To Watch Today  ACIA  AMSC  TWLO  VCEL,opinion,"Acacia Communications Inc  NASDAQ ACIA   a swing trade of ours  looks like it may have just stuck its head out with a little engulfing reversal bar on Monday  popping 1 02  or 2 34   to 44 64  on 292 071 shares traded  Volume was not big  but technicals are pretty good  We may have come out of out a consolidation  but in order to get a confirmation  it needs to take out 45 1 2  Watch this one going forward  because if it does take out 45 1 2  it could quickly get you to 47  50  or thereabout 
American Superconductor Corporation  NASDAQ AMSC   also one of our swing trades  broke out  pulled back  formed a wedge  and popped off its support on Friday  followed through on Monday with a gain of 49 cents  or 6   to 8 85  on 118 712 shares traded  I m looking for an extension to test 10 00  and then 11 00 
Twilio Inc  NYSE TWLO  popped with a little breakaway on Monday  jumping 6 79  or 8 4   to 87 41  on 7 million shares  There s a little bit of resistance  The follow through for Tuesday could be tested around 91 1 2  followed by 99  That s my target 
Vericel Corp Ord  NASDAQ VCEL  broke out on Monday  bouncing 1 04  or 6   to 17 88  on 1 4 million shares  and we put a swing on it  I liked that little pop  then a breakaway gap to double tops to multi month resistance area  then the consolidation zone  it raised to the 50  and ran up in a consolidation where the moving average crosses over and moves up  I think it s headed to 22 
Stocks on the long side included Acacia Communications  Inc   ACIA   American Superconductor Corporation  AMSC   BioScrip  Inc   BIOS   Etsy  Inc   ETSY   Houghton Mifflin Harcourt Company  HMHC   JinkoSolar Holding Co   Ltd   JKS   Newell Brands Inc   NWL   SunPower Corporation  SPWR   TAL Education Group  TAL   The Trade Desk  Inc   TTD   Twilio Inc   TWLO   Twitter  Inc   TWTR   Vericel Corporation  VCEL   Vodafone Group Plc  LON VOD   and Vivint Solar  Inc   VSLR  
Watch video here ",2018-11-26,Harry Boxer,https://www.investing.com/analysis/acia-amsc-twlo-vcel-200362517,200362517
107053,328568,VCEL,Small Cap ETFs   Stocks To Outperform This Holiday Season ,opinion,"The holiday season is off to a great start this year buoyed by a digital shopping boom  Online sales jumped 28  to  3 7 billion on Thanksgiving Day and 23 6  to a record  6 22 billion on Black Friday  according to Adobe  NASDAQ ADBE  Analytics  This makes Thursday the fastest growing day for e commerce sales in history and marks the first Friday after Thanksgiving Day in history to see more than  2 billion in sales from smartphones  About 33 5  of e commerce sales came from mobile devices compared with 29 1  in 2017 Despite the optimism  the three major indices logged in their biggest losses in a Thanksgiving week since 2011  with the Dow Jones  the S P 500 and the Nasdaq Composite Index tumbling 4 4   3 8  and 4 3   respectively  The decline came amid myriad woes  especially the ongoing trade tensions between the United States and China  global growth worries  FAANG sell off as well as the worsening oil price rout  read    However  if we go by history  stocks are expected to rise  recovering all their losses over the next month  This is especially true as the Dow Jones Industrial Average  the S P 500  the Nasdaq 100 and the Russell 2000 indexes all generally climb between Thanksgiving and Christmas Eve  according to data from Kensho  The Dow Jones has returned an average of 1 93  in the time period since 1990  while the S P 500 and the Nasdaq gained 1 77  and 1 66  respectively  The Russell 2000 has outperformed during the holidays  rising on average 2 46  
The outperformance of the small caps seems to hold true this year given that these pint sized stocks are well insulated from international headwinds  which we are currently seeing  These are considered safe and better plays if any political issue or economic turmoil creeps into the picture  Additionally  the strength in U S  dollar  which makes domestic goods more expensive overseas  will also support the small cap surge  The Russell 2000 Index was down only 0 5  in a Thanksgiving week Further  a booming economy will provide a lift to stock prices  This is especially true as the American economy has been on a solid pace of growth with robust job creation  strong GDP growth  a 50 year low unemployment rate  the fastest pace of wage gains in nearly a decade  and rising consumer and business confidence  While third quarter GDP growth slowed to 3 5  from 4 2  in the second quarter amid growing headwinds from trade  it marks the best two quarter stretch in four years  With this  the economy is on pace for the fastest annual growth in 13 years Small cap stocks generally lead the way on an improving American economy though they are extremely volatile and could lead to huge losses compared with large and mid cap counterparts in a short span  read    Given this  we have presented five ETFs   stocks that are expected to outdo this holiday season  All these carry a Zacks Rank  1  Strong Buy  or  2  Buy   suggesting their continued outperformance ETF PicksSchwab U S  Small Cap ETF   NS SCHA  This ETF tracks the Dow Jones U S  Small Cap Total Stock Market Index Zacks ETF Rank   1Expense Ratio  0 50 AUM   7 5 billionOne Week Return  1 8 Vanguard Small Cap ETF   TO VB  This ETF follows the CRSP US Small Cap Index  read    Zacks ETF Rank   1Expense Ratio  0 05 AUM   22 5 billionOne Week Return  1 8 iShares S P Small Cap 600 Growth ETF This product offers exposure to U S  small cap stocks of companies whose earnings are expected to grow at an above average rate relative to the market by tracking the S P SmallCap 600 R  Growth Index Zacks ETF Rank   2Expense Ratio  0 25 AUM   6 billionOne Week Return  1 5 Vanguard Small Cap Value ETF   TO VB  This fund follows the CRSP US Small Cap Value Index that measures the return of small capitalization value stocks  read    Zacks ETF Rank   1Expense Ratio  0 07 AUM   12 8 billionOne Week Return  1 2 iShares Core S P Small Cap ETF This fund tracks the S P SmallCap 600 Index Zacks ETF Rank   1Expense Ratio  0 07 AUM   41 9 billionOne Week Return  1 2 Stock PicksVericel Corporation   NASDAQ VCEL  It is focused on developing patient specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions  You can see  Zacks Rank   1Growth Score  BMarket Cap   775 05 millionOne Week Return  7 5 Malibu Boats Inc    NASDAQ MBUU  It operates as a designer  manufacturer and marketer of sport boats primarily in the United States Zacks Rank   2Growth Score  AMarket Cap   987 9 millionOne Week Return  6 8 Upland Software Inc    NASDAQ UPLD  It is a provider of cloud based Enterprise Work Management software that helps organizations plan  manage and execute projects and work Zacks Rank   1Growth Score  BMarket Cap   627 6 millionOne Week Return  4 9 QuinStreet Inc    NASDAQ QNST  It is a provider of online direct marketing and media services offering online messaging  email broadcasting  search engine marketing  and brand management services  read    Zacks Rank   2Growth Score  AMarket Cap   739 8 millionOne Week Return  3 7 eGain Corporation   NASDAQ EGAN  This company provides customer engagement solutions and offers web customer interaction applications  social customer interaction applications and contact center applications Zacks Rank   1Growth Score  AMarket Cap   198 2 millionOne Week Return  2 7 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-11-27,Zacks Investment Research,https://www.investing.com/analysis/smallcap-etfs--stocks-to-outperform-this-holiday-season-200363048,200363048
107054,328569,VCEL,The Zacks Analyst Blog Highlights  Vericel  Malibu Boats  Upland Software  QuinStreet And EGain,opinion,For Immediate ReleaseChicago  IL   November 29  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Vericel Corp    NASDAQ VCEL    Malibu Boats Inc    NASDAQ MBUU    Upland Software Inc    NASDAQ UPLD    QuinStreet Inc    NASDAQ QNST   and eGain Corp    NASDAQ EGAN   Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Wednesday s Analyst Blog Small Cap Stocks to Outperform This Holiday SeasonThe holiday season is off to a great start this year buoyed by a digital shopping boom  Online sales jumped 28  to  3 7 billion on Thanksgiving Day and 23 6  to a record  6 22 billion on Black Friday  according to Adobe  NASDAQ ADBE  Analytics  This makes Thursday the fastest growing day for e commerce sales in history and marks the first Friday after Thanksgiving Day in history to see more than  2 billion in sales from smartphones  About 33 5  of e commerce sales came from mobile devices compared with 29 1  in 2017 Despite the optimism  the three major indices logged in their biggest losses in a Thanksgiving week since 2011  with the Dow Jones  the S P 500 and the Nasdaq Composite Index tumbling 4 4   3 8  and 4 3   respectively  The decline came amid myriad woes  especially the ongoing trade tensions between the United States and China  global growth worries  FAANG sell off as well as the worsening oil price rout  read    However  if we go by history  stocks are expected to rise  recovering all their losses over the next month  This is especially true as the Dow Jones Industrial Average  the S P 500  the Nasdaq 100 and the Russell 2000 indexes all generally climb between Thanksgiving and Christmas Eve  according to data from Kensho  The Dow Jones has returned an average of 1 93  in the time period since 1990  while the S P 500 and the Nasdaq gained 1 77  and 1 66  respectively  The Russell 2000 has outperformed during the holidays  rising on average 2 46  The outperformance of the small caps seems to hold true this year given that these pint sized stocks are well insulated from international headwinds  which we are currently seeing  These are considered safe and better plays if any political issue or economic turmoil creeps into the picture  Additionally  the strength in U S  dollar  which makes domestic goods more expensive overseas  will also support the small cap surge  The Russell 2000 Index was down only 0 5  in a Thanksgiving week Further  a booming economy will provide a lift to stock prices  This is especially true as the American economy has been on a solid pace of growth with robust job creation  strong GDP growth  a 50 year low unemployment rate  the fastest pace of wage gains in nearly a decade  and rising consumer and business confidence  While third quarter GDP growth slowed to 3 5  from 4 2  in the second quarter amid growing headwinds from trade  it marks the best two quarter stretch in four years  With this  the economy is on pace for the fastest annual growth in 13 years Small cap stocks generally lead the way on an improving American economy though they are extremely volatile and could lead to huge losses compared with large and mid cap counterparts in a short span  read    Given this  we have presented five stocks that are expected to outdo this holiday season  All these carry a Zacks Rank  1  Strong Buy  or  2  Buy   suggesting their continued outperformance Stock PicksVericel Corp It is focused on developing patient specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions  You can see  Zacks Rank   1Growth Score  BMarket Cap   775 05 millionOne Week Return  7 5 Malibu Boats Inc It operates as a designer  manufacturer and marketer of sport boats primarily in the United States Zacks Rank   2Growth Score  AMarket Cap   987 9 millionOne Week Return  6 8 Upland Software Inc It is a provider of cloud based Enterprise Work Management software that helps organizations plan  manage and execute projects and work Zacks Rank   1Growth Score  BMarket Cap   627 6 millionOne Week Return  4 9 QuinStreet Inc It is a provider of online direct marketing and media services offering online messaging  email broadcasting  search engine marketing  and brand management services  read    Zacks Rank   2Growth Score  AMarket Cap   739 8 millionOne Week Return  3 7 eGain Corp This company provides customer engagement solutions and offers web customer interaction applications  social customer interaction applications and contact center applications Zacks Rank   1Growth Score  AMarket Cap   198 2 millionOne Week Return  2 7 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week  About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-vericel-malibu-boats-upland-software-quinstreet-and-egain-200363438,200363438
107055,328570,VCEL,Zacks com Highlights  Vericel  Mitek  Vanda Pharmaceuticals  Mosaic And Spirit Airlines,opinion,For Immediate ReleaseChicago  IL   November 29  2018   Stocks in this week s article include  Vericel Corp    NASDAQ VCEL    Mitek Systems Inc    NASDAQ MITK    Vanda Pharmaceuticals Inc    NASDAQ VNDA    The Mosaic Co    NYSE MOS   and Spirit Airlines Inc    NYSE SAVE   Screen of the Week of Zacks Investment Research 5 Stocks with Recent Price Strength for a Stouter Portfolio In the stock game  winning means reaching a higher price   However  striking the right chord each time needs a fair amount of luck No matter how disciplined and systematic investors are  equity market volatility will always manage to get the better of them  While a few lucky ones rake in the moolah  others fall victim to ad hoc strategies One could resort to commonly used techniques to find beaten down stocks that have the potential to recover faster than others  However  even such investment choices bear the risk of disappointment  Particularly  one could fall into the value trap if the hidden weaknesses in selected stock are not identified So  wouldn t it be a safer strategy to look for stocks that are winners currently and have the potential to gain further Sounds a good idea  Here is how to execute it One should primarily target stocks that have recently been on a bull run  Actually  stocks seeing price strength recently have a high chance of carrying the momentum forward If a stock is continuously witnessing an uptrend  there must be a solid reason or else it would have probably crashed  So  looking at stocks that are capable of beating the benchmark that they have set for themselves seems rational However  recent price strength alone cannot create the magic  Therefore  you need to set other relevant parameters to create a successful investment strategy Here s how you should create the screen to shortlist the current as well as the potential winners And that s what we re screening for today For the rest of this Screen of the Week article please visit Zacks com at  Get the remaining stocks on the list and start putting this and other ideas to the test  It can all be done with the Research Wizard stock picking and back testing software The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/zackscom-highlights-vericel-mitek-vanda-pharmaceuticals-mosaic-and-spirit-airlines-200363433,200363433
107056,328571,VCEL,4 Best Stocks To Buy For Superb Earnings Acceleration,opinion,Right from the top brass to research analysts  earnings growth interests all  This is because earnings are a measure of the money a company is making  Notably  earnings are essentially revenues that the company generates after deducting the cost of production over a given period of time Earnings acceleration  however  works even better when it comes to boosting the stock price  Studies have shown that a majority of successful stocks had seen acceleration in earnings before a rally in stock price Future OutperformersBasically  earnings acceleration is the incremental growth in earnings of a company  In other words  if the rate of a company s quarter over quarter earnings growth increases within a stipulated frame of time  it can be referred to as earnings acceleration In case of earnings growth  you pay for something that is already reflected in the stock price  But  earnings acceleration helps spot stocks that haven t caught the attention of investors yet  which once secured will invariably lead to a rally in the share price  This is because earnings acceleration considers both direction and magnitude of growth rates Increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period of time  Meanwhile  a sideways percentage of earnings growth indicates a period of consolidation or slowdown  while a decelerating percentage of earnings growth may at times drag prices down This is the reason why earnings acceleration should be viewed as a key metric for share price outperformance Screening Parameters Let s look at stocks for which the last two quarter over quarter percentage EPS growth rates exceed the growth rates of the previous periods  The projected quarter over quarter percentage EPS growth rates are also expected to be higher than the previous periods  growth rates EPS   Projected Growth  Q1   Q0  greater than EPS   Growth  Q0   Q 1   The projected growth rate for the current quarter  Q1  over the completed quarter  Q0  has to be greater than the growth rate from the completed quarter  Q0  over one quarter ago  Q 1  EPS   Growth  Q0   Q 1  greater than EPS   Growth  Q 1   Q 2   The growth rate for the completed quarter  Q0  over one quarter ago  Q 1  has to be greater than the growth rate from one quarter ago  Q 1  over two quarters ago  Q 2  EPS   Growth  Q 1   Q 2  greater than EPS   Growth  Q 2   Q 3   The growth rate from one quarter ago  Q 1  over two quarters ago  Q 2  has to be greater than the growth rate from two quarters ago  Q 2  over three quarters ago  Q 3  In addition to this  we have added the following parameters Current Price greater than or equal to  5  This screens out low priced stocks Average 20 day volume greater than or equal to 50 000  High trading volume implies that the stocks have adequate liquidity The above criteria narrowed down the universe of around 7 735 stocks to only 10  Here are the top four stocks Helen of Troy Limited   NASDAQ HELE   designs  develops  imports  markets  and distributes a portfolio of consumer products worldwide  The company sports a Zacks Rank  2  Buy   The company s expected earnings growth rate for the current year is 8 8  compared with the  industry s estimated decline of 1 5  Vericel Corporation   NASDAQ VCEL   develops  manufactures  markets  and sells patient specific expanded cellular therapies to repair and regenerate damaged tissues and organs  The company has a Zacks Rank  1  Strong Buy   The company  which is part of the  industry  is projected to return 66 7  both this quarter and the next  You can see  Mobile Mini  Inc    NASDAQ MINI   provides portable storage and specialty containment solutions  The company holds a Zacks Rank  2  The company s expected earnings growth rate for the current year is 44 8  compared with the  industry s estimated rise of 21 5  Logitech International S A    NASDAQ LOGI   designs  manufactures  and markets products that allow people to connect through music  gaming  video  computing  and other digital platforms worldwide  The company flaunts a Zacks Rank  2  The company s expected earnings growth rate for the current year is 16 9  compared with the  industry s projected rally of 8 5  You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at ,2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/4-best-stocks-to-buy-for-superb-earnings-acceleration-200363494,200363494
107057,328572,VCEL,Small Cap ETFs   Stocks To Outperform This Holiday Season  Revised  ,opinion,"The holiday season is off to a great start this year buoyed by a digital shopping boom  Online sales jumped 28  to  3 7 billion on Thanksgiving Day and 23 6  to a record  6 22 billion on Black Friday  according to Adobe  NASDAQ ADBE  Analytics  This makes Thursday the fastest growing day for e commerce sales in history and marks the first Friday after Thanksgiving Day in history to see more than  2 billion in sales from smartphones  About 33 5  of e commerce sales came from mobile devices compared with 29 1  in 2017 Despite the optimism  the three major indices logged in their biggest losses in a Thanksgiving week since 2011  with the Dow Jones  the S P 500 and the Nasdaq Composite Index tumbling 4 4   3 8  and 4 3   respectively  The decline came amid myriad woes  especially the ongoing trade tensions between the United States and China  global growth worries  FAANG sell off as well as the worsening oil price rout  read    However  if we go by history  stocks are expected to rise  recovering all their losses over the next month  This is especially true as the Dow Jones Industrial Average  the S P 500  the Nasdaq 100 and the Russell 2000 indexes all generally climb between Thanksgiving and Christmas Eve  according to data from Kensho  The Dow Jones has returned an average of 1 93  in the time period since 1990  while the S P 500 and the Nasdaq gained 1 77  and 1 66  respectively  The Russell 2000 has outperformed during the holidays  rising on average 2 46  
The outperformance of the small caps seems to hold true this year given that these pint sized stocks are well insulated from international headwinds  which we are currently seeing  These are considered safe and better plays if any political issue or economic turmoil creeps into the picture  Additionally  the strength in U S  dollar  which makes domestic goods more expensive overseas  will also support the small cap surge  The Russell 2000 Index was down only 0 5  in a Thanksgiving week Further  a booming economy will provide a lift to stock prices  This is especially true as the American economy has been on a solid pace of growth with robust job creation  strong GDP growth  a 50 year low unemployment rate  the fastest pace of wage gains in nearly a decade  and rising consumer and business confidence  While third quarter GDP growth slowed to 3 5  from 4 2  in the second quarter amid growing headwinds from trade  it marks the best two quarter stretch in four years  With this  the economy is on pace for the fastest annual growth in 13 years Small cap stocks generally lead the way on an improving American economy though they are extremely volatile and could lead to huge losses compared with large and mid cap counterparts in a short span  read    Given this  we have presented five ETFs   stocks that are expected to outdo this holiday season  All these carry a Zacks Rank  1  Strong Buy  or  2  Buy   suggesting their continued outperformance ETF PicksSchwab U S  Small Cap ETF   NS SCHA  This ETF tracks the Dow Jones U S  Small Cap Total Stock Market Index Zacks ETF Rank   1Expense Ratio  0 05 AUM   7 5 billionOne Week Return  1 8 Vanguard Small Cap ETF   TO VB  This ETF follows the CRSP US Small Cap Index  read    Zacks ETF Rank   1Expense Ratio  0 05 AUM   22 5 billionOne Week Return  1 8 iShares S P Small Cap 600 Growth ETF This product offers exposure to U S  small cap stocks of companies whose earnings are expected to grow at an above average rate relative to the market by tracking the S P SmallCap 600 R  Growth Index Zacks ETF Rank   2Expense Ratio  0 25 AUM   6 billionOne Week Return  1 5 Vanguard Small Cap Value ETF   TO VB  This fund follows the CRSP US Small Cap Value Index that measures the return of small capitalization value stocks  read    Zacks ETF Rank   1Expense Ratio  0 07 AUM   12 8 billionOne Week Return  1 2 iShares Core S P Small Cap ETF This fund tracks the S P SmallCap 600 Index Zacks ETF Rank   1Expense Ratio  0 07 AUM   41 9 billionOne Week Return  1 2 Stock PicksVericel Corporation   NASDAQ VCEL  It is focused on developing patient specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions  You can see  Zacks Rank   1Growth Score  BMarket Cap   775 05 millionOne Week Return  7 5 Malibu Boats Inc    NASDAQ MBUU  It operates as a designer  manufacturer and marketer of sport boats primarily in the United States Zacks Rank   2Growth Score  AMarket Cap   987 9 millionOne Week Return  6 8 Upland Software Inc    NASDAQ UPLD  It is a provider of cloud based Enterprise Work Management software that helps organizations plan  manage and execute projects and work Zacks Rank   1Growth Score  BMarket Cap   627 6 millionOne Week Return  4 9 QuinStreet Inc    NASDAQ QNST  It is a provider of online direct marketing and media services offering online messaging  email broadcasting  search engine marketing  and brand management services  read    Zacks Rank   2Growth Score  AMarket Cap   739 8 millionOne Week Return  3 7 eGain Corporation   NASDAQ EGAN  This company provides customer engagement solutions and offers web customer interaction applications  social customer interaction applications and contact center applications Zacks Rank   1Growth Score  AMarket Cap   198 2 millionOne Week Return  2 7 
 We are reissuing this article to correct a mistake  The original article  issued on November 28  2018  should no longer be relied upon   
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-12-02,Zacks Investment Research,https://www.investing.com/analysis/smallcap-etfs--stocks-to-outperform-this-holiday-season-revised-200364439,200364439
107059,328574,VCEL,4 Best Stocks That Flaunt Superb Earnings Acceleration,opinion,Constant earnings growth captivates almost everyone  right from the top brass to research analysts  This is because earnings are a measure of the money a company is making  Notably  earnings are essentially revenues that the company generates after deducting the cost of production over a given period of time Earnings acceleration  however  works even better when it comes to lifting the stock price  Studies show that a majority of successful stocks see acceleration in earnings before an uptick in the stock price Future OutperformersSo  what is earnings acceleration  It is the incremental growth in a company s earnings per share  EPS   In other words  if the rate of a company s quarter over quarter earnings growth increases within a stipulated frame of time  it can be called earnings acceleration In case of earnings growth  you pay for something that is already reflected in the stock price  But  earnings acceleration helps spot stocks that haven t caught the attention of investors yet  which once secured will invariably lead to a rally in the share price  This is because earnings acceleration considers both direction and magnitude of growth rates Increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period of time  Meanwhile  a sideways percentage of earnings growth indicates a period of consolidation or slowdown  while a decelerating percentage of earnings growth may at times drag prices down Hence  earnings acceleration should be viewed as a key metric for share price outperformance The Winning StrategyLet s look at stocks for which the last two quarter over quarter percentage EPS growth rates exceed the growth rates of the previous periods  The projected quarter over quarter percentage EPS growth rates are also expected to be higher than the previous periods  growth rates EPS   Projected Growth  Q1   Q0  greater than EPS   Growth  Q0   Q 1   The projected growth rate for the current quarter  Q1  over the completed quarter  Q0  has to be greater than the growth rate from the completed quarter  Q0  over one quarter ago  Q 1  EPS   Growth  Q0   Q 1  greater than EPS   Growth  Q 1   Q 2   The growth rate for the completed quarter  Q0  over one quarter ago  Q 1  has to be greater than the growth rate from one quarter ago  Q 1  over two quarters ago  Q 2  EPS   Growth  Q 1   Q 2  greater than EPS   Growth  Q 2   Q 3   The growth rate from one quarter ago  Q 1  over two quarters ago  Q 2  has to be greater than the growth rate from two quarters ago  Q 2  over three quarters ago  Q 3  In addition to this  we have added the following parameters Current Price greater than or equal to  5  This screens out the low priced stocks Average 20 day volume greater than or equal to 50 000  High trading volume implies that the stocks have adequate liquidity The above criteria narrowed down the universe of around 7 735 stocks to only 26  Here are the top four stocks TEGNA Inc    NYSE TGNA   operates as a media company in the United States  The company has a Zacks Rank  2  Buy   The Zacks Consensus Estimate for current year earnings rose 7 1  in the past 60 days Vericel Corporation   NASDAQ VCEL   is a commercial stage biopharmaceutical company  The company holds a Zacks Rank  1  Strong Buy   The Zacks Consensus Estimate for current year earnings moved 29  up in the past 60 days Mobile Mini  Inc    NASDAQ MINI   provides portable storage and specialty containment solutions  The company has a Zacks Rank  2  The Zacks Consensus Estimate for current year earnings rose 0 6  in the past 60 days  You can see  Splunk Inc    NASDAQ SPLK   provides software solutions that enable organizations to gain real time operational intelligence  The company holds a Zacks Rank  2  The Zacks Consensus Estimate for current year earnings moved 7 3  up in the past 60 days You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material Disclosure  Performance information for Zacks  portfolios and strategies are available at ,2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/4-best-stocks-that-flaunt-superb-earnings-acceleration-200369035,200369035
107061,328576,VCEL,4 Stocks To Watch  CETX  EBS  LCI  OPK,opinion,"The markets had a pretty good day Tuesday morning  It pulled back in the afternoon  but it was a strong day on Wall Street  A lot of our stocks did well  so let s take a look at some of them 
Cemtrex Inc  NASDAQ CETX  had a nice pop  especially near the end of the day when it really ran  It moved up  pulled back to where I gave you a swing on it at about 4 80  then it pulled down for another few minutes  and then exploded 71 cents  or 16   to 5 05  on 1 5 million shares traded  I put a swing on it because I think it s going to run up to the 5 3 4 6 range  and maybe even 7 00  or more  eventually 
Emergent Biosolutions Inc  NYSE EBS   another stock I put a swing trade on  because this one seemed like the big break away gap on the contract announcement  and then the inside day on Monday  got it ready to pop 74 cents  or 2 2   to 34 21  on 659 037 shares traded on Tuesday  I m looking for a test of 37  and maybe the low 40 s  It has 10  short 
Lannett Com  NYSE LCI  popped 85 cents  or 3 5   to 24 95  on 843 834 shares traded  I think I may have put a swing on it prematurely  What I missed was the lack of volume and lack of technicals  Beware  I am going to put strict stops on this one underneath 22 22 40  I don t want to see it under that line because then it could roll over  The good thing is that it moved up across moving averages  which it crossed over  and then popped on Tuesday  before backing off nearly a point  Right now  it could be one big wedge and break down from it  That s why I want the stop protection  The upside  however  if it does accelerate  could see this stock trading in the 29 30 range  It has 6 7   which could fuel the fire  so to speak 
Opko Health Inc  NASDAQ OPK  is looking good  It has a long term head and shoulders  or basing pattern  and it may be coming out of it right now  It traded 26 cents  or 2 2   to 11 91  on 6 2 million shares traded  That s a total of 13 million shares traded in the last two sessions with Monday s pop  and then the follow through on Tuesday  I then put a swing on it on Tuesday  I think it has room for 13  15  and 17  potentially  as targets  It has 18 6  
Stocks on the long side included Argan Inc  NYSE AGX   Achaogen Inc  NASDAQ AKAO   Asure Software Inc  NASDAQ ASUR   Avianca Hldgs Adr Rep 8 Prf  NYSE AVH   Cemtrex Inc  NASDAQ CETX   Callon Petroleum Company  NYSE CPE   Emergent BioSolutions Inc   NYSE EBS   Lannett Company  Inc   NYSE LCI   Organovo Holdings  Inc   NASDAQ ONVO   Opko Health  Inc   OPK   Orbotech Ltd   NASDAQ ORBK   Terex Corporation  NYSE TEX   Tailored Brands  Inc   NYSE TLRD   Tower Semiconductor Ltd   NASDAQ TSEM   Western Digital Corporation  NASDAQ WDC   and Vericel Corporation  NASDAQ VCEL  ",2016-12-15,Harry Boxer,"https://www.investing.com/analysis/cetx,-ebs,-lci,-opk--stock-charts-to-watch-200169782",200169782
107062,328577,VCEL,The FDA  Small Cap Catalyst Or Small Cap Killer ,opinion,"This particular bureaucracy neither gives nor takes  Data do  If a drug works  the company that develops it will do well  If a drug doesn t work  the company that develops it had better have a diversified pipeline 
Many of the 4 000 or so drugs in the Food and Drug Administration s  FDA  approval system are there because of the work of intrepid scientists employed by small cap companies 
Some are so unique they gain special status  Some generate positive clinical trial results  Some generate negative clinical trial results 
It can be a long  cumbersome  and expensive gauntlet  But  efficacy  can be an elusive target when it comes to complex chemical interactions 
FDA decisions are  ultimately  driven by data  not by some nefarious desire to stymie innovators  and entrepreneurs  desire to save lives 
Here s how it works 
Phase 1 trials are about safety  They typically involve 20 80 patient volunteers  with testing designed to identify a candidate drug s most frequent side effects and how it s metabolized and excreted 
Phase 2 emphasizes effectiveness  with a patient volunteer pool numbering in the hundreds and the trial often placebo controlled  The goal is to gather sufficient data to determine whether the drug actually works for its intended purpose  Safety and short term side effects are also evaluated 
Phase 3 trials typically involve thousands of patient volunteers  Here  more data are gathered about safety and effectiveness  while testing is fine tuned to assess impact on different populations at varying dosages and in combination with other drugs 
Many of the 4 000 or so drugs in the Food and Drug Administration s  FDA  approval system are there because of the work of intrepid scientists employed by small cap companies 
The FDA s New Drug Application  NDA  review involves a meeting with a drug s sponsor  a formal submission of the drug  a formal review of all research on safety and effectiveness  an evaluation of drug labeling for appropriate information  and an inspection of the facility where the drug will be manufactured 
Following all that  the FDA will either approve the application or issue a response letter  The former is  obviously  positive  The latter is not 
Even after a drug is approved  the FDA continues to monitor it  as  it s not possible to predict all of a drug s effects during clinical trials   During the Phase 4 post marketing monitoring stage  a drug sponsor submits periodic safety updates 
 Fast Track Designation  is an alternative FDA process designed to facilitate faster approval of drugs developed for serious diseases that  address an unmet medical need  
 Breakthrough Therapy Designation  speeds the development and review of drugs meant for a serious condition where  preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint s   
 Accelerated Approval  regulations allow FDA to base approval of drugs  for serious conditions that fill an unmet medical need on whether the drug has an effect on a surrogate or an intermediate clinical endpoint  
 Priority Review  is granted in cases where a drug  if approved  represents  a significant improvement in safety or effectiveness in the treatment of a serious condition  
Meanwhile   Orphan Drug Designation  provides clinical trial tax credits  user fee waivers  and exclusivity to incentivize development of drugs for rare diseases 
Phase 3 is perhaps the most important catalyst  Results here  are very important for biotech companies  as they offer insight into the real effectiveness of a drug in human patients and drives  sic  the ultimate market valuation  
At all points along the way  there are opportunities to make profits and suffer losses  based on positive or negative decisions and results 
Analysis by Thomas J  Hwang  formerly a researcher at Harvard Medical School and an associate in healthcare investment with Bain Capital Ventures  supports the conclusion that trial data matter for stock prices of publicly traded companies 

The release of clinical trial results is an economically significant event and has meaningful effects on market value for large biopharmaceutical companies  Stock return underperformance due to negative events is greater in magnitude and persists longer than abnormal returns due to positive events  suggesting asymmetric market reactions 

Although his study was limited to  large biopharmaceutical companies   including Amgen Inc   NASDAQ AMGN   Bristol Myers Squibb Company  NYSE BMY   Eli Lilly and Company  NYSE LLY   Merck  NYSE MRK   and Pfizer Inc   NYSE PFE   Hwang notes   These findings confirm and extend previous scholarship on the significant market reactions to clinical trial results for biotechnology companies with few compounds in development  
At all points along the way  there are opportunities to make profits and suffer losses  based on positive or negative decisions and results 
FDA catalysts affect large  as well as small cap drug developers  At the same time  research suggests small caps will react more violently in terms of changes in market capitalization than large caps 
Indeed  we have ample supporting evidence developed just in the first two weeks of December 
Take  for instance  Achaogen Inc  NASDAQ AKAO   now a  377 million company 
Achaogen announced on December 12 that its Phase 3 trial of plazomicin  for patients with complicated urinary tract infections and acute pyelonephritis   met the FDA objective of noninferiority compared with meropenem and achieved superiority for the European Medicines Agency  EMA  primary efficacy endpoints  
The stock closed at  5 25 on December 9  closed at  13 03 on December 12  traded as high as  16 20 on the day after the announcement  and is now priced at  14 00  That s a gain of 166  
Vericel Corp Ord  NASDAQ VCEL   now valued at  140 million  received FDA approval for its Maci  autologous cultured chondrocytes on porcine collagen membrane  therapy  for the repair of symptomatic  full thickness cartilage defects of the knee in adult patients  on December 13 
The stock closed at  2 60 on December 13  opened at  4 00 on December 14  hit  4 55 that day  and closed at  4 10  It s now trading at  3 50  up 34  in two days 
Voyager Therapeutics Inc  NASDAQ VYGR  surged as much as 33  on positive interim results for its Phase 1b trial of VY AADC01 for advanced Parkinson s disease  announced on December 7 
On December 8  the stock gapped up at the open to  17 50 and traded as high as  18 25  This was a short term bounce   illustrating the fleeting momentum such early clinical results provide   as the stock is now trading at  14 69  That s still a 7  gain since the results were announced 
Note that stocks often move days before announcements of key clinical trial results  possibly the result of insider knowledge of key clinical trial data 
Corcept Therapeutics Incorporated  NASDAQ CORT   which develops drugs for severe metabolic  psychiatric  and oncologic disorders  bounced from  6 92 on November 1 to  10 00 on November 14 
But it didn t announce efficacy data from its Phase 1 2 trial of its drug mifepristone in patients with metastatic or triple negative breast cancer until December 10 
The stock has settled back a bit  closing at  8 51 yesterday 
An FDA determination of special status can also be a powerful catalyst 
On September 19  2016  the FDA  granted  Sarepta Therapeutics Inc  NASDAQ SRPT   accelerated approval  for its Exondys 51 injection therapy   the first drug approved to treat Duchenne muscular dystrophy  DMD  
Exondys 51 enjoyed Fast Track Designation  Priority Review  and Orphan Drug Designation from the FDA 
According to the FDA   Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping  which affects about 13  of the population with DMD  
In its press release announcing the approval  the FDA further explained 

Exondys 51 was approved under the accelerated approval pathway  which provides for the approval of drugs that treat serious or life threatening diseases and generally provide a meaningful advantage over existing treatments  Approval under this pathway can be based on adequate and well controlled studies showing the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit to patients  how a patient feels or functions or whether they survive   This pathway provides earlier patient access to promising new drugs while the company conducts clinical trials to verify the predicted clinical benefit 

The approval was controversial  as many FDA insiders opposed it 
Dr  Janet Woodcock  director of the FDA s Center for Drug Evaluation and Research  recently explained to CNBC that this surprise approval is indicative of the agency s  broader move toward patient focused drug development  
Sarepta s share price nearly doubled on September 19  opening at  28 81 and trading as high as  56 18 before closing at  48 94 
FDA catalysts affect large  as well as small cap drug developers  At the same time  research suggests small caps will react more violently in terms of changes in market capitalization than large caps 
Stocks move on negative data  too 
Cerecor Inc   CERC  tanked on November 30 but didn t release its top line clinical results from its nicotine withdrawal Phase 2 clinical trial of CERC 501  an oral  potent  and selective kappa opioid receptor antagonist  until December 5 
As Cerecor noted in its announcement 

The trial did not meet its primary objective in nicotine withdrawal  CERC 501 was well tolerated  Based on this favorable side effect profile  and as previously planned  Cerecor intends to move forward with development of CERC 501 in its primary indication  as an adjunctive treatment of major depressive disorder  MDD  

The stock opened at  5 12 on November 29  against a 52 week high of  5 60  and closed at  4 72 that day  On November 30  it gapped lower at the open to  2 34  traded as low as  1 90  and closed at  2 08 
By December 5  the day the data emerged  it was trading as low as  1 10  It closed at  1 16 yesterday 
On December 12  Proteon Therapeutics Inc  NASDAQ PRTO  closed at  9 90  At 8 30 a m  ET on December 13  it released top line Phase 3 data for its chronic kidney disease therapy  which  did not meet its primary endpoint of improved primary unassisted patency compared to placebo  
The stock opened that day at  2 90 and is now trading at  2 05 
Ophthotech  NASDAQ OPHT  tanked after its own Phase 3 failure  as  no benefits were observed  from its Fovista treatment for  wet age related macular degeneration  
It closed at  38 77 on December 9  It opened at  6 24 on December 12 and is now trading at  4 86 ",2016-12-16,Wall Street Daily,https://www.investing.com/analysis/the-fda:-small-cap-catalyst-or-small-cap-killer-200169951,200169951
107063,328578,VCEL,4 Stocks To Watch  ABEO  COOL  IMGN  SGMO,opinion,"Abeona Therapeutics Inc   NASDAQ ABEO  had a big pop on Tuesday  popping 1 75  or 18 4   to 11 25  on 2 8 million shares traded  It had a breakout and a thrust through the July high  and when it crossed the 10 24 area  it closed a dollar higher  At this point  I m looking for the 14 15 range as the next target  maybe even higher  There s 20 84  
Majesco Entertainment Company  NASDAQ COOL   a swing trade of ours  was acting really well on Tuesday  We put it out to you at 23 81 on Aug 15  and now it s trading 6 points higher  reaching as high 29 92 on Tuesday  It was up 1 35  or 4 8   to 29 46  on 140 001 shares traded  It s high in June was 30 09  If it gets through that  the targets are 33 4  maybe as high as the high 30 s over the next few weeks going forward  It has 6  
Swing trade ImmunoGen  Inc   NASDAQ IMGN  was put out on May 16 at 4 88  It reached up to 8 00  pulled back in a 3 wave corrective move  and then broke out on Tuesday  jumping 1 12  or 17   to 7 58  on 13 million shares traded  That s the biggest volume since January  Targets are 9 1 2 and 12 1 2  It has 5 5  
Sangamo Therapeutics  Inc   NASDAQ SGMO  is also looking good  This is a swing trade from May 11 at 6 68  On Tuesday  it was up 1 30  or 11 3   to 12 80  on 3 3 million shares traded  reaching a high of 12 90  My current targets are 11 1 2 and 13  My target going forward is 17  It had 3 6  
On the long side  stocks included Abeona Therapeutics Inc   ABEO   Agnico Eagle Mines Limited  NYSE AEM   Majesco Entertainment Company  COOL   Corcept Therapeutics Incorporated  NASDAQ CORT   Catalent  Inc   NYSE CTLT   Fate Therapeutics  Inc   NASDAQ FATE   Amicus Therapeutics  Inc   NASDAQ FOLD   First Solar  Inc   NASDAQ FSLR   Health Insurance Innovations  Inc   NASDAQ HIIQ   ImmunoGen  Inc   IMGN   Juno Therapeutics Inc   NASDAQ JUNO   KEMET Corporation  NYSE KEM   Kratos Defense   Security Solutions  Inc   NASDAQ KTOS   Movado Group  Inc   NYSE MOV   Puma Biotechnology  Inc   NASDAQ PBYI   Sangamo Therapeutics  Inc   NASDAQ SGMO   Swift Transportation Company  NYSE SWFT   Vericel Corporation  NASDAQ VCEL   and YRC Worldwide Inc   NASDAQ YRCW  ",2017-08-30,Harry Boxer,https://www.investing.com/analysis/abeo-cool-imgn-sgmo-200210299,200210299
107064,328579,VCEL,4 Stocks To Watch  DLB  LOXO  NVCR  SIEN,opinion,"Dolby Laboratories  Inc   NYSE DLB  made an explosive move on Wednesday  jumping 5 17  or 9 58   to 59 11  on 3 8 million shares traded  This is a stock that had been basing from 2011 to 2016  and thren traded in the 34 5 zone  It popped out  pulled back  and formed a one year consolidation  Wednesday s moved is significant because it takes out all levels to the 70 dollar range  which is my next target  It has 5  
Swing trade Loxo Oncology  Inc   NASDAQ LOXO  is doing phenomenal  We put it out as a swing  it ran up to my target  consolidated for a couple months  and then on Wednesday  it had a significant breakout  popping 11 61  or 15 46   to 86 72  on 2 1 million shares traded  closing 4 points off the high  on the second biggest up day in almost a year  I think it wants to go higher  Look for something in the high 90 s  around 99 100  and then 120ish 
NovoCure Limited  NASDAQ NVCR  broke out on Wednesday  gaining another 1 30  or 6 36   to 21 75  on 1 5 million shares traded  This is a swing trade that has been in play since June  If it extends  I m looking for 28  and eventually 32  It has 8  short 
Sientra  Inc   NASDAQ SIEN  is doing great  It popped another 2 43  or 19   to 15 01  on 789 611 shares traded  and is moving up the ladder  going from 10 to 15 in the last couple weeks  If it breaks out above the 11 1 2 range  the immediate target is 17 1 2 ish 
On the long side  stocks included AXT Inc   NASDAQ AXTI   Ballard Power Systems Inc   NASDAQ BLDP   Baozun Inc   NASDAQ BZUN   Dolby Laboratories  Inc   NYSE DLB   Emerge Energy Services  NYSE EMES   Juno Therapeutics Inc   NASDAQ JUNO   Loxo Oncology  Inc   NASDAQ LOXO   MicroVision  Inc   NASDAQ MVIS   NovoCure Limited  NASDAQ NVCR   Sientra  Inc   NASDAQ SIEN   TravelCenters of America LLC  NASDAQ TA   VelocityShares 3x Lng Crude Oil ETN New  NYSE UWT   and Vericel Corporation  NASDAQ VCEL  ",2017-09-15,Harry Boxer,https://www.investing.com/analysis/dlb-loxo-nvcr-sien-200213407,200213407
107065,328580,VCEL,4 Biotechs Breaking Out,opinion,"Biotech stocks we follow were big movers Tuesday  and here are four to watch for continued upside 
Regenxbio Inc   NASDAQ RGNX  exploded up 18   or  5 95  to close at  37 40 on very heavy volume of 1 2 million shares traded Tuesday  That is more than three times its average volume  The move was a follow through from Monday s surge that came on news that business partner  AveXis  NASDAQ AVXS   also in the gene therapy space  is being acquired by Novartis  NYSE NVS   Next target is  40 41 
Tandem Diabetes Care Inc   NASDAQ TNDM  tore up 22   or  1 29  closing at  7 01 on huge volume of 6 6 million shares traded  That is more than four times its average volume  The move came as the medical device company announced preliminary financial results indicating insulin pump shipments increased by 56 percent and sales by 42 percent in the first quarter of 2018 compared the first quarter of 2017  Having moved up with high velocity  the stock has appreciated a whopping 89  in value in the last three weeks  On March 23  Robert W  Baird upgraded the stock from neutral to outperform with a price target lifted from  3 to  7  Price is at the top of its channel  so expect a potential short term pullback  Next target   8 50 
Vericel Corporation Corp   NASDAQ VCEL   sprang out of a bull flag consolidation Tuesday  closing up 11  to  12 00 on 1 3 million shares traded  The move came with news that the tissue therapy company s CEO will present at an industry investor day on April 17  Price had leapt dramatically on March 5 after the biopharma company reported record revenues and improved net income for the 2017 fourth quarter and full year  If the stock can close above the March 7 high of  12 80  the next target is  15 
Xencor Inc   NASDAQ XNCR  rose out of a 18 day falling wedge pattern to close the day up 6   or  1 78  at  30 19 on casual volume of 452 700 shares traded on no news  The clinical stage biopharmaceutical company is developing engineered monoclonal antibodies for the treatment of autoimmune diseases  asthma and allergic diseases and cancer  Price has risen nearly 40  in the last two months  With a close above  31 50  the next target is  34 50 ",2018-04-11,Harry Boxer,https://www.investing.com/analysis/4-biotechs-breaking-out-200304733,200304733
107066,328581,VCEL,4 Stocks To Watch  AMRN  CRC  FATE  GERN,opinion,"Amarin Corporation PLC  NASDAQ AMRN  had a big day on Monday on fantastic drug news  jumping 9 41  or 315   to 12 40  on 162 million shares  It ran up and pulled back on Monday morning  based out  ran up sharply into the close  and then in after hours it s in a bull coil that tells me this stock is not done yet by any means  I think  on a swing trade this is going to be 15 and 18  It could quickly run up to 14 15  My targets are at 15 1 2 16  and then the 19 1 2 20 zone 
California Resources Corp  NYSE CRC  is fantastic and one of the best performing stocks all year  A year ago in August  this stock was under 7 00  it ran up to 22  and change  dropped down into the high teens  exploded to the high 40 s  dropped back down into the high 20 s  and is running again  popping 6 98  or 18   to 46 58  on 6 million shares on Monday  If I m not mistaken  this stock is headed for a breakout above the 49 range  and then a run into the mid 60 s  low 70 s eventually 
Fate Therapeutics Inc  NASDAQ FATE  broke out on Monday  gaining 1 71  or 12   to 16 28  on 1 8 million shares  A current swing of ours  it almost looks like it s going to break to 25  My targets right now are 20 and 25 going forward  It has a right handed extended V  an inverse head and shoulders  and a breakout with volume 
Geron Corporation  NASDAQ GERN  popped 74 cents  or 13 1 2   to 6 20  on 12 million shares on Monday  It s looking better  My target was 6 85 90  Now I m looking at 8 1 2 9 going forward 
Stocks on the long side included Aurora Cannabis Inc  TO ACB   Canopy Growth Corporation  NYSE CGC   AcelRx Pharmaceuticals  Inc   NASDAQ ACRX   Akcea Therapeutics  Inc   NASDAQ AKCA   Advanced Micro Devices  Inc   NASDAQ AMD   Amarin Corporation plc  NASDAQ AMRN   Arrowhead Pharmaceuticals  Inc   NASDAQ ARWR   Boston Scientific Corporation  NYSE BSX   California Resources Corporation  NYSE CRC   Dicerna Pharmaceuticals  Inc   NASDAQ DRNA   Ecopetrol S A   NYSE EC   Fate Therapeutics  Inc   NASDAQ FATE   Geron Corporation  NASDAQ GERN   Idera Pharmaceuticals  Inc   NASDAQ IDRA   Omeros Corporation  NASDAQ OMER   uniQure N V   NASDAQ QURE   TransEnterix  Inc   NYSE TRXC   Vericel Corporation  NASDAQ VCEL   Viking Therapeutics  Inc   NASDAQ VKTX   Intrexon Corporation  NYSE XON   and Zafgen  Inc   NASDAQ ZFGN  ",2018-09-25,Harry Boxer,https://www.investing.com/analysis/amrn-crc-fate-gern-200345439,200345439
107067,328582,VCEL,Aastrom Biosciences  Financial Implications And Cash ,opinion,Focusing onto orphan diseasesThe review led by new CEO  Mr Colangelo  concluded that the REVIVE chronic limb ischaemia Phase III study will take too long to recruit and is beyond the financial resources available  With no immediate partner  Aastrom  ASTM  stopped the study  Aastrom is now reducing its headcount and cash burn by about 50   The focus is now on the Phase II ischaemic cardiomyopathy  IDC  orphan indication  The ixCELL DCM study will cost about  7m  If recruitment completes by early 2014  the data will presented in Q215  Funding of  35m until the end of 2015 will be needed ixCELL DCM  Ph II ischaemic dilated cardiomyopathyIDC is a chronic indication where the heart distends and becomes weaker due to poor blood supply  The treatments are either transplant  rare  or  increasingly common  implanting artificial heart devices  LVAD   In the exploratory IMPACT study  ixmyelocel T improved some indicators of heart performance  The Phase IIb  ixCELL DCM study in 108 patients across 30 sites using catheter injection of cells  It is expected to enrol its first patient in early Q213 and complete recruitment in Q114  to present data in Q215  A Phase III will be needed  as IDC is an orphan condition  a single pivotal study might be run  Other orphan conditions are being evaluated and new indications for ixmyelocel T are expected to be announced REVIVE is deadThe REVIVE study in chronic limb ischaemia was behind on patient recruitment  with only 40 patients in its first year out of 594  Given the cost and the uncertain time to completion  a partner was urgently needed to both fund the trial and to speed recruitment  As no immediate partner was found  REVIVE was stopped Financial implications and cashIn 2014  the cash use is expected to be about  15m per year  2013 will be transitional with  6m in Q1 likely   5m in Q2 including lay off costs and final REVIVE payments then about  8m for H2  Cash at the end of 2012 was  13 7m with  2 4m from an  At the Market  facility in Q1  Eastern Capital has first claim over about  44m of the value and holds over 22  of the voting rights  The Eastern pref stock converts at  3 50 per share  Funding of  35m will be needed until the end of 2015 to complete ixCELL DCM and perhaps partner it for Phase III Valuation  A fundable high risk trialEdison has suspended its valuation of Aastrom until the situation is clearer  The ischaemic DCM indication is focused  potentially high value but high risk To Read the Entire Report Please Click on the pdf File Below ,2013-04-03,Edison,https://www.investing.com/analysis/aastrom-biosciences:-financial-implications-and-cash-161485,161485
107069,328584,VCEL,Vericel Dives  Should You Worry ,opinion,"Vericel  NASDAQ VCEL  is having a rough day in the market today  In fact  at 9 53  the stock was trading at  4 05 per share after a loss of  0 28 per share or 6 46  thus far today  With such steep declines on the stock s value  investors are likely asking themselves   Should I be concerned   Today  we ll talk about why VCEL is falling  whether or not you should be concerned  and what we can expect to see from the stock moving forward  So  let s get right to it   
Why Is VCEL Tanking 
As mentioned above  Vericel is having a rough start to the week in the market today  Naturally  when I see such a big decline  I start to do a bit of research to see what it is that is causing the decline  So  one of the first things I did this morning was start researching VCEL to see what was going on  Believe it or not  there was not one piece of bad news  Fundamentally  the stock is flawless and should not be falling  However  there is a good reason for the declines   
Price movement in the market tends to happen through a series of overreactions  When we hear good news about a publicly traded company  we generally expect to see the value of the stock associated with that company skyrocket  However  it s not unlikely that after big gains we see declines  This is exactly what we re seeing from VCEL  Late last week  Vericel skyrocketed in a big way  gaining more than 80   and for good reason 
VCEL recently announced Phase 2b results from the ixCELL DCM study into ixmyelocel T as a treatment for heart failure do to ischemic dilated cardiomyopathy  also known as DCM  Through the study  VCEL achieved its primary endpoint of demonstrating a reduction in the total number of deaths  cardiovascular hospitalizations or unplanned outpatient and emergency department visits as a result of acutedecompensated heart failure during a 12 month period following treatment  In a statement  Dr  David Recker  Chief Medical Officer at VCEL had the following to say   

The result of the ixCELL DCM study  which we believe is the largest randomized cell therapy trial to treat congestive heart failure completed to date  demonstrated statistically significant and clinically meaningful reduction in cardiac events in patients who received treatment with ixmyelocel T compared to placebo     We are very excited about these study results given the lack of treatment options for end stage heart failure patients 

Should You Be Concerned About VCEL Declines 
While I understand that a decline of more than 6  in any stock will generally lead to fear among investors  this particular case is different  As mentioned above  there is no fundamental data supporting a decline  What we re seeing is a basic correction to an overreaction that sent the stock further than it should have climbed  Sure VCEL deserved gains  but over 80  is a big move  and investors are correcting the growth  bringing the stock down to a more sustainable rate before growth can continue 
What I Expect To See From Here
Moving forward  I have a relatively bullish opinion with regard to what we can expect to see from Vericel  First and foremost  I m very impressed with what we ve seen from ixmyelocel T in all phases of studies  The treatment is a much needed one in the medical field and looks like it will be approved in the long run  which will lead to big gains for VCEL  All in all  VCEL has a great team  great product  and great management  So  I see no reason to expect to see anything but growth in the stock moving forward ",2016-03-14,Joshua Rodriguez,https://www.investing.com/analysis/vericel-(vcel)-stock-dives:-should-you-be-concerned-200121516,200121516
